Newsmakers

Biodexa (NASDAQ: BDRX)Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract – Now 12-Month Data

CARDIFF, UK July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making good progress with eRapa™, […]

Newsmakers

Kazia Therapeutics (NASDAQ: KZIA) Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma SYDNEY, July 10, 2024  — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused […]

Newsmakers

Ocean Power Technologies (NASDAQ: OPTT) Partners with Unique Group for Autonomous Vehicle Services in the Middle East

Deploying commercially available solutions for Offshore Energy customers MONROE TOWNSHIP, N.J., July 02, 2024– Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine power, data, […]

Newsmakers

Loop Media (NASDAQ: LPTV) Announces Strategic Partnership with Outpatient Imaging Affiliates to Enhance Patient Experience in Imaging Centers Nationwide

GLENDALE, Calif., June 27, 2024—-Loop Media, Inc. (“Loop Media”) (NYSE American: LPTV), a leading multichannel streaming CTV platform that provides curated music videos, sports highlights, news, premium entertainment channels, and digital signage for businesses, and […]

Newsmakers

Senti Bio (NASDAQ: SNTI) Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia SOUTH SAN FRANCISCO, Calif., July 01, 2024  — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti […]

Newsmakers

Enovix (NASDAQ: ENVX) Signs Agreement to Deliver High-Performance Batteries for Mixed Reality Headset

FREMONT, Calif., June 25, 2024  — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has signed an agreement with a leading California-based technology company to provide silicon batteries and packs for […]

Newsmakers

Alnylam (NASDAQ: ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

− Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively – − Reduced All-Cause Mortality by 36% and 35% in the Overall and […]

Newsmakers

Eos Energy (NASDAQ: EOSE) Announces Strategic Investment of up to $315.5 Million from Cerberus to Propel Eos’ Expansion and Path to Profitability

Significant strategic investment supports Company’s growth plans in an accelerating long duration battery storage market and enables Eos to restructure existing debt TURTLE CREEK, Pa. and NEW YORK, June 24, 2024  — Eos Energy Enterprises, […]

Newsmakers

Sunrise (NASDAQ: EPOW) Achieves Significant Milestone with Delivery of 5,800 Tons to HiTHIUM, a Global Leading Energy Storage Battery Manufacturer

ZIBO, China, June 24, 2024 — Sunrise New Energy Co., Ltd. (“Sunrise New Energy”, the “Company”, “we” or “our”) (NASDAQ: EPOW), today announced the successful delivery of 5,800 tons of energy storage material to Xiamen […]

Newsmakers

Revelation Biosciences (NASDAQ: REVB) Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity- -Gemini was safe and well tolerated at pharmacologically active doses- -Phase 1 results enable further development across multiple indications- SAN DIEGO, June […]